Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Sponsor
Kantonsspital Aarau
Study ID
NCT02072057
Phase
PHASE2
Status
Terminated

Conditions

  • Cancer Cachexia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The aim of this study is to investigate the effects and safety of Ruxolitinib, a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) inhibitor for the treatment of tumor-associated cachexia in chronic wasting diseases.

Key Dates

First listed
Feb 26, 2014
Start date
Apr 20, 2014
Status verified
Feb 2019
Primary completion
Nov 30, 2018
Completion
Nov 30, 2018

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib
    Interventional arm

Primary Outcome Measure

Body weight [ Time Frame: 3 months ]

Related Studies